[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benign-prostatic-hyperplasia-bph\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benign-prostatic-hyperplasia-bph":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,43,77,103,127,150,185,212,237,261,288,313,340,361],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644456","steam-map-1-study---steam-therapy-with-mri-and-ai-assisted-planning-100644456",false,"NCT07663344","STEAM-MAP 1 Study - Steam Therapy With MRI and AI-assisted Planning","Prospective Feasibility Trial on MRI-TRUS Fusion Water Vapour Ablation for Benign Prostatic Hyperplasia (STEAM-MAP 1 Study - Steam Therapy With MRI and AI-assisted Planning)","Inclusion Criteria:\n\n* Age 30-80 years old with symptomatic BPH.\n* Prostate volume 30-80 mL (TRUS\u002FMRI\u002FUS)\n* Suitable for Rezum.\n* Able to consent and comply with follow-up to 1 month.\n* With prior prostate MRI within 2 years\n\nExclusion Criteria:\n\n* Known\u002Fsuspected prostate cancer requiring oncologic management.\n* Prior prostate surgery impacting urethral anatomy within 12 months.\n* Prior implant affecting urethral anatomy.\n* Active UTI or untreated bacteriuria pre-op.\n* Uncorrectable coagulopathy; inability to manage antithrombotics.\n* Severe medical comorbidity precluding endoscopy.","MALE","30 Years","80 Years",{"count":20,"type":21},15,"ESTIMATED","INTERVENTIONAL",[24],"NA","The STEAM-MAP 1 Study is a single-arm, prospective feasibility trial evaluating the integration of MRI-transrectal ultrasound (TRUS) fusion guidance into Rezūm water vapor thermal therapy for men with symptomatic benign prostatic hyperplasia (BPH).",[27],"Benign Prostatic Hyperplasia (BPH)",[29],"Water vapor thermal therapy","NOT_YET_RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-23","ACTUAL",{"date":36,"type":21},"2026-06-01",{"date":38,"type":21},"2028-03-31",{"name":40,"class":41},"Chinese University of Hong Kong","OTHER",3,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100640806","a-prospective-comparative-study-evaluating-the-safety-and-efficacy-of-transurethral-thulium-fiber-laser-holmium-laser-and-bipolar-enucleation-of-large-sized-prostate-100640806","NCT07627178","A Prospective Comparative Study Evaluating the Safety and Efficacy of Transurethral Thulium Fiber Laser, Holmium Laser and Bipolar Enucleation of Large Sized Prostate","Inclusion Criteria:\n\n* Male patients diagnosed with BPH\n* Clinical diagnosis of BPH with lower urinary tract symptoms.\n* IPSS ≥ 20 (severe symptoms)\n* Maximum urinary flow rate (Qmax) ≤ 10 mL\u002Fs\n* Prostate volume \\>100 mL (measured by transrectal ultrasound)\n* Failed medical therapy and fit for operation\n\nExclusion Criteria:\n\n* Prostate cancer (current or history).\n* Previous prostate surgery\n* Previous urethral surgery.\n* Neurogenic bladder dysfunction.\n* Active urinary tract infection.\n* Severe cardiovascular disease (ASA Class IV).\n* Previous pelvic radiation.\n* Urethral stricture\n* Urinary bladder stones.",true,{"count":51,"type":21},90,[24],"This study compares the safety and efficacy of three endoscopic enucleation techniques for large prostates (\\>100 mL) in patients with benign prostatic hyperplasia (BPH): Thulium Fiber Laser Enucleation (ThuFLEP), Holmium Laser Enucleation (HoLEP), and Bipolar Enucleation (B-TUEP). Ninety male patients with severe lower urinary tract symptoms (IPSS ≥20, Qmax ≤10 mL\u002Fs) who failed medical therapy will be randomized 1:1:1 into three groups of 30. Primary outcomes include IPSS, quality of life score, maximum flow rate (Qmax), and post-void residual at 1, 3, and 6 months postoperatively. Secondary outcomes include operative time, enucleation efficiency, blood loss, catheterization duration, hospital stay, and complication rates assessed by the Clavien-Dindo classification.",[27,55,56],"Lower Urinary Tract Symptom","Bladder Outlet Obstruction",[58,59,60,61,62,63,64,65],"Prostate Enucleation","ThuLEP","HOLEP","Bi-TUEP","TFL","BPH Surgery","IPSS","Uroflowmetry","RECRUITING","2026-06-03",{"date":69,"type":34},"2026-06-05",{"date":71,"type":34},"2025-10-21",{"date":73,"type":21},"2027-05-30",{"name":75,"class":41},"Tanta University",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100641021","to-establish-the-safety-and-effectiveness-of-the-alpfa-grail-pfa-system-for-treating-symptomatic-benign-prostate-hyperplasia-bph-also-known-as-an-enlarged-prostate-100641021","NCT07592299","To Establish the Safety and Effectiveness of the ALPFA GRAIL PFA System for Treating Symptomatic Benign Prostate Hyperplasia (BPH) Also Known as an Enlarged Prostate.","A Prospective Randomized Pivotal Trial of the ALPFA Medical Prostate Ablation System Compared With Cystoscopy in Men With Symptomatic Benign Prostatic Hyperplasia","REBOUND","Inclusion Criteria: Study subjects are required to meet all the following inclusion criteria to participate in this study as determined by the Investigator:\n\n1. ≥ 45 years of age on the day of enrollment.\n2. Symptomatic BPH meeting all of the following criteria determined within 30 days preceding enrollment and after fulfilling the concomitant medication washout period(s):\n\n   1. Symptom Score: Baseline IPSS score ≥13\n   2. Flow Rate: Single uroflow test with a minimum voided volume ≥ 125 mL and a Qmax ≥ 5 mL\u002Fsec and ≤ 12 mL\u002Fs\n   3. Residual: ultrasound-determined PVR of ≤ 250 mL\n3. Prostate size 25-150 g, measured by transrectal ultrasound.\n4. Willing and able to provide consent and comply with study requirements.\n\nExclusion Criteria:Subjects will be excluded from the study if they meet any one of the following exclusion criteria, as determined by the Investigator:\n\n1. Medical conditions that would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or confound data or its interpretation, including but not limited to:\n\n   1. Cardiovascular:\n\n      * History of clinically significant heart failure (NYHA III\u002FIV)\n      * Uncontrolled arrhythmia.\n      * Stroke, TIA, myocardial infarction, unstable angina, percutaneous coronary intervention, or any cardiac surgery within 180 days of enrollment.\n      * Uncontrolled hypertension\n   2. Renal: Serum creatinine \\> 2.0 mg\u002FdL or any history of renal dialysis or renal transplant.\n   3. Metabolic: Clinically uncontrolled diabetes mellitus or a baseline HbA1c ≥ 8.0%, or clinically significant liver disease.\n   4. Non-urologic cancer: Active malignancy, or within 3 years of enrollment, a history of treated malignancy now in full remission, except basal cell or squamous cell carcinoma of the skin.\n   5. Respiratory: Severe lung disease or respiratory illness requiring hospitalization.\n   6. Immunosuppression: Known immunosuppression, including but not limited to AIDS, immunosuppressive medication, or current chemotherapy.\n   7. Transplant: Solid organ or hematologic transplant or currently being evaluated for an organ transplant.\n   8. Substance abuse: Active alcoholism or drug addiction.\n2. Urologic conditions that would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or confound data or its interpretation, including but not limited to:\n\n   1. Operative: Previous prostate surgery or interventional procedure, including but not limited to BPH surgery, radiation, laser, prostate arterial embolism, balloon dilatation, or hyperthermic treatment, or prostate biopsy within 40 days of the Index Procedure.\n   2. Infection: Active urinary tract infection at the time of the Index Procedure (may be treated and enrolled upon negative urine culture).\n   3. Incontinence: History of urinary incontinence.\n   4. Retention: Requires indwelling catheter or intermittent catheterization to void or had an episode of spontaneous urinary retention within 30 days of enrollment.\n   5. Prostatitis: History of prostatitis within 2 years of enrollment.\n   6. Cystolithiasis: Active bladder stones\n   7. Neurogenic bladder: Neurogenic or atonic bladder or sphincter, including etiologies of uncontrolled diabetes, Parkinson's disease, multiple sclerosis, cerebrovascular accident, or polyneuropathy.\n   8. Anatomic abnormality: Prior or current urethral stricture, meatal stenosis, bladder neck contracture, or other urologic anatomic abnormalities that would interfere with planned treatment or confound subsequent assessment.\n   9. Implants: Any urinary tract implants including stents, sutures, penile implants, or artificial sphincters.\n   10. Hematuria: Hematuria without a known contributing factor within 90 days of the Index Procedure.\n3. Bladder cancer: Actively being treated or suspected cancer of the bladder.\n4. Baseline PSA \\> 10 ng\u002FmL or confirmed or suspected prostate cancer (Subjects with a PSA level above 2.5 ng\u002FmL, or age specific, or local reference ranges should have prostate cancer excluded to the Investigator's satisfaction following the site's standard of care.\n5. Prior pelvic or rectal interventions:\n\n   1. Previous pelvic irradiation or radical pelvic surgery\n   2. Previous rectal surgery (other than hemorrhoidectomy) or a history of rectal disease that may be impacted by Index Procedure.\n6. Peri-procedural anticoagulation: Unable to stop anti-platelet or anticoagulation treatment for the Index Procedure per site standard of care.\n7. Subjects who cannot or will not comply with the following washout medication requirements within the time period specified prior to enrollment:\n\n   1. 24-Hours:\n\n      * i. Taking phenylephrine or pseudoephedrine within 24 hours of the Baseline evaluation and Index Procedure.\n   2. 1 Week:\n\n      * i. Antihistamine, anticonvulsant, or antispasmodics medications within 1 week of enrollment unless documented on a stable (unchanged) for 180 days prior to enrollment.\n   3. 2 Weeks:\n\n      * i. Use of alpha blockers or daily dosage of PDE5 inhibitors (tadalafil \\[Cialis\\]) for BPH within 2 weeks prior to enrollment.\n      * ii. Use of anticholinergics or beta-3 adrenergic receptor agonists (e.g., mirabegron, vibegron) within 2 weeks prior to enrollment, unless documented on a stable dose for 30 days prior to enrollment.\n   4. 3 Months:\n\n      * i. Taking estrogen, drugs producing androgen suppression, or androgens within 90 days prior to enrollment, unless documented on a stable dosage for at least 90 days prior to enrollment.\n      * ii. Use of Type II 5-alpha reductase inhibitor medication (e.g., finasteride \\[Proscar, Propecia\\]) within 90 days of enrollment OR anticipated use within the first 12 months of follow-up.\n   5. 6 Months:\n\n      * i. Use of any Type I 5-alpha reductase inhibitor medication (e.g., dutasteride \\[Avodart\\]) within 180 days prior to enrollment OR anticipate use within the first 12 months of follow-up.\n      * ii. Taking tricyclic antidepressants that are not on a stable dose for the 180 days prior to enrollment OR anticipate stopping or changing treatment in the first 12 months of follow-up.\n8. Subjects who wish to maintain their fertility.\n9. Current or anticipated enrollment in any other randomized or interventional clinical study (registry or retrospective studies permitted).\n10. Vulnerable populations, including individuals who are incarcerated or institutionalized.Any physical, psychological, or developmental impairment (e.g., developmental delay) that, in the investigator's opinion, would compromise the subject's ability to provide informed consent, comply with study procedures, or complete patient-reported outcome measures.","45 Years",{"count":87,"type":21},250,[24],"The main goal of this study is to evaluate the ALPFA GRAIL™ Pulsed Field Ablation (PFA) System for treatment of enlarged prostate (BPH) symptoms. The study will involve up to 250 male participants who have urinary problems caused by BPH and whom are greater than 40 years of age in up to 30 investigational centers across the US,Canada and European Union.",[27],[92],"enlarged prostate","2026-05-11",{"date":95,"type":34},"2026-05-18",{"date":97,"type":21},"2026-08",{"date":99,"type":21},"2032-12",{"name":101,"class":102},"ALPFA Medical","INDUSTRY",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100420619","post-market-study-to-assess-itind-safety-in-comparison-to-urolift-100420619","NCT04757116","Post-Market Study to Assess iTind Safety in Comparison to UroLift","A Post-Market, Prospective, Randomized, Controlled, Multicenter International Study to Assess the Safety of the Temporarily Implanted Nitinol Device (iTind) Compared to the UroLift® System in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)","MT-08","Inclusion Criteria:\n\n1. Diagnosis of lower urinary tract symptoms presumed to be secondary to benign prostatic enlargement causing bladder outlet obstruction for which treatment is recommended\n2. Willing and able to provide informed consent\n3. Males ≥ 50 years of age or older\n4. PSA \\\u003C 4 ng\u002Fdl, ng\u002Fml or if the PSA is 4 - 10 ng\u002Fdl, ng\u002Fml, prostate cancer must be ruled out to the satisfaction of the Principal Investigator (PI) by local standard of care methods within prior 6 months\n5. Prostate volume up to 75 cc (inclusive) documented by cross-sectional imaging (TRUS, MRI, etc.). Results from standard of care imaging may be accepted up to 6 months prior to Screening if the subject was not on 5-alpha reductase inhibitors (5ARIs) at that time\n6. International Prostate Symptom Score (IPSS) ≥ 13\n7. Maximum urinary flow rate (Qmax) of ≤ 15 mL\u002Fsec and ≥ 5 mL\u002Fsec (voided volume must be ≥ 125 mL)\n8. Willing and able to complete all study visits including questionnaires at baseline and at follow-up visits\n\nExclusion Criteria:\n\n1. History of prostate cancer or suspected, should be ruled out to the satisfaction of the PI by local standard of care methods within prior 6 months\n2. Confirmed or suspected bladder cancer within the last 2 years\n3. History of acute bacterial prostatitis within the last 2 years\n4. Median lobe obstruction of the prostate as confirmed by cross-sectional imaging\n5. PSA value \\> 10 ng\u002Fdl, ng\u002Fml\n6. Contraindicated for iTind or UroLift as determined by the PI\n7. Neurogenic bladder and\u002For sphincter abnormalities due to Parkinson's disease, multiple sclerosis, cerebral vascular accident, diabetes or other neurological disorders that affect bladder function\n8. Clinically significant bladder diverticulum\n9. Diagnosed with urethral stricture, meatal stenosis, bladder neck contracture, rectal disease, artificial urinary sphincter, incompetent sphincter, urinary incontinence due to incompetent sphincter\n10. Prior rectal surgery (other than hemorrhoidectomy) or history of rectal disease if the therapy may potentially cause injury to sites or previous rectal surgery (e.g., if a transrectal probe is used), pelvic radiotherapy or radical pelvic surgery, urinary diversion surgery, prostate surgery, balloon dilation, urethral stent implantation, laser prostatectomy, or any other invasive treatment to the prostate, or penile prosthesis that may prevent insertion of the iTind or UroLift device\n11. An active urinary tract infection\n12. Hematuria or cystolithiasis within the last 3 months\n13. Prostate volume \\> 75 cc\n14. Post-void residual volume (PVR) \\> 250 mL\n15. Actively using catheterization or unable to void naturally\n16. Unable to complete the required washout period for alpha blockers\n17. Taking anti-platelet or anticoagulants (except low dose aspirin - 81 mg - 100 mg) within the last 7 days prior to randomization\n18. Known or suspected allergy to nickel, titanium or polyester\u002Fpolypropylene","50 Years",{"count":113,"type":21},206,[24],"The study objective is to evaluate the safety of the iTind device comparied to UroLift.",[27],"2026-05-05",{"date":119,"type":34},"2026-05-06",{"date":121,"type":34},"2022-09-26",{"date":123,"type":21},"2031-12-31",{"name":125,"class":102},"Olympus Corporation of the Americas",19,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":134,"maxAge":4,"enrollmentInfo":135,"targetDuration":137,"studyType":138,"phases":4,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":76},"100626037","the-flow-registry-100626037","NCT07430423","The FLOW Registry.","The FLOW Registry: Functional and Longitudinal Outcomes With Waterjet Ablation","Inclusion Criteria:\n\n* Male sex\n* ≥18 years of age\n* Diagnosis of benign prostatic hyperplasia\n* Scheduled to undergo or have already undergone Aquablation as part of routine clinical care or any ongoing clinical trials\n* Aquablation performed with ultrasound guided, robotic assisted waterjet. Newer methods and instrumentation continue to be developed to ablate tissue, and these energy sources can be entered into the registry as clinical use begins.\n\nExclusion Criteria:\n\n* Under 18 Years of age.","18 Years",{"count":136,"type":21},3000,"10 Years","OBSERVATIONAL","The purpose of this study is to create a database and prospective registry for data collection on patients with benign prostatic hyperplasia undergoing Aquablation of the prostate. All patients undergoing Aquablation of the prostate will be enrolled in the registry. Historical data from 1\u002F1\u002F2024- 11\u002F30\u002F2025 will be added through chart review. Current and future patient data will be collected through chart review during the subject's clinical care. Only data available in the electronic medical record will be collected and no additional data will be collected for research purposes. No biospecimens will be collected, and there are no physical risks from study participation.",[27],"2026-04-17",{"date":143,"type":34},"2026-04-20",{"date":145,"type":21},"2026-05",{"date":147,"type":21},"2036-12",{"name":149,"class":41},"University of Chicago",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":158,"maxAge":4,"enrollmentInfo":159,"targetDuration":161,"studyType":138,"phases":4,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":76},"100611609","minimally-invasive-prostate-interventions-registry-mist-study-100611609","NCT07242807","Minimally Invasive Prostate Interventions Registry (MIST Study)","Evaluation of Clinical and Functional Outcomes After Minimally Invasive Prostate Interventions: A Multicenter Prospective REDCap Registry (MIST Study)","MIST","Inclusion Criteria:\n\n* Male patients aged ≥40 years\n* Diagnosis of benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) or benign prostatic obstruction (BPO)\n* Undergoing a minimally invasive prostate intervention (Rezum, UroLift, Aquablation, PAE, iTind, TPLA, TUNA, TUMT) as part of standard clinical care\n* Ability and willingness to attend scheduled follow-up visits\n* Prospective participants able to provide written informed consent\n* Retrospective cases eligible if data are fully de-identified and inclusion is approved by local ethics\u002FIRB authorities\n\nExclusion Criteria:\n\n* Active urinary tract infection at the time of treatment\n* ASA physical status ≥5\n* Prior pelvic radiotherapy resulting in severe bladder dysfunction\n* Severe cognitive impairment or inability to participate in follow-up\n* Missing essential baseline data (for retrospective entries)\n* Patients receiving experimental or investigational prostate devices or therapies outside routine clinical care","40 Years",{"count":160,"type":21},2000,"72 Months","This study is a multicenter prospective patient registry designed to evaluate clinical, functional, and safety outcomes after minimally invasive prostate interventions (MIST) performed for benign prostatic obstruction (BPO) secondary to benign prostatic hyperplasia (BPH). The interventions included in this registry represent standard-of-care treatment options and may include Rezum water vapor therapy, UroLift prostatic urethral lift, Aquablation, prostatic artery embolization (PAE), iTind, transperineal laser ablation (TPLA), transurethral needle ablation (TUNA), and transurethral microwave therapy (TUMT).\n\nThe registry collects standardized data using a secure REDCap platform from participating international centers. Data elements include demographic characteristics, comorbidities, medication use, laboratory parameters, prostate volume assessments, uroflowmetry, post-void residual measurements, patient-reported symptom scores, sexual function assessments, intraoperative details, complications (classified using Clavien-Dindo), and postoperative recovery parameters. Follow-up visits occur at 1, 3, 6, 12, 24, and 36 months, with an optional extended follow-up at 72 months to assess long-term durability and reintervention-free survival.\n\nThe primary aim of the study is to evaluate improvements in urinary symptoms (IPSS), quality of life, maximum urinary flow rate (Qmax), and post-void residual volume (PVR) following MIST procedures. Secondary objectives include assessing perioperative safety, catheterization duration, predictors of treatment success or failure, need for reintervention, and long-term preservation of continence and sexual function.\n\nThis registry is observational and does not assign or modify any treatment. All procedures are performed based on local clinical practice and physician judgment. Prospective participants provide informed consent. Data collected will be used to generate real-world evidence to guide patient selection, optimize procedural outcomes, and compare clinical performance across different minimally invasive prostate interventions.",[27,164,165],"Minimal Invasive Surgery","LUTS",[156,167,168,169,170,171,172,173,174,175],"Minimally Invasive Surgical Therapy","Rezum","UroLift","Aquablation","Prostatic Artery Embolization","iTind","TPLA","Benign Prostatic Hyperplasia","Lower Urinary Tract Symptoms","2026-03-28",{"date":178,"type":34},"2026-03-31",{"date":180,"type":21},"2026-03-25",{"date":182,"type":21},"2031-12-30",{"name":184,"class":41},"Necmettin Erbakan University",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":158,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":76},"100594221","laser-ablation-a-salvage-treatment-for-obstructive-benign-prostatic-hyperplasia-100594221","NCT07016620","Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia","In-Office Transperineal Laser Ablation (TPLA) as a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia (BPH) After Minimally Invasive Surgical Therapies (MIST)","ECHOLASER","Inclusion Criteria:\n\n* Men \\> 40 years old\n* History of Minimally invasive BPH procedure within the last 5 years.\n* IPSS \\>= 12\n* Prostate Volume 30 - 80 gr as assessed by CT, MRI or TRUS.\n* PSA \\\u003C4 or for patients with PSA 4-10 evaluation has been performed to rule out prostate cancer using biopsy, MRI, biomarker, or surgeon judgement. Labs within 1 year of study initiation\n* PVR \\> 150cc or reduced flow on uroflow likely due to obstruction based on clinical judgement\n* IIEF-6\\>or =10 without medication\n\nExclusion Criteria:\n\n* Indwelling catheter or intermittent catheterization\n* History of urethral strictures\n* Previous diagnosis of Prostate cancer\n* Active UTI or prostatitis\n* Hypoactive detrusor function\n* Neurogenic bladder (secondary to stroke, Multiple Sclerosis, Parkinson's disease, Spinal cord injury)\n* Ejaculatory dysfunction (retrograde ejaculation, anorgasmia or anejaculation)\n* Prior traditional BPH surgery (TURP, PVP, Aquablation, HOLEP, SP)\n* Presence of obstructive median lobe\n* Moderate to severe or severe ED based on IIEF-6\u002FSHIM (SHIM of 10)\n* Peyronie's disease",{"count":194,"type":21},20,"Benign prostatic hyperplasia (BPH) is a common condition affecting aging men, often leading to lower urinary tract symptoms (LUTS). While Minimally Invasive Surgical Therapies (MIST) procedures offer less invasive alternatives to traditional surgery, some patients experience symptom recurrence or require further intervention due to lack of adequate relief of obstruction. Treatment of persistent obstruction after MIST therapy (BPH salvage therapy) typically requires surgical intervention like transurethral resection of prostate (TURP). This study proposes to evaluate the effectiveness of in-office transperineal laser ablation (TPLA) using the Echolaser system as a minimally invasive treatment option for these patients, potentially avoiding more invasive surgical procedures. The Cleveland Clinic sees a high volume of BPH salvage patients, making this an ideal setting for this research.",[27],[198,199,200,201,202],"benign prostatic hyperplasia (BPH)","lower urinary tract symptoms (LUTS)","transperineal Laser Ablation (TPLA)","Minimally Invasive Surgical Therapies (MIST)","salvage treatment","2026-02-03",{"date":205,"type":34},"2026-02-05",{"date":207,"type":34},"2026-01-12",{"date":209,"type":21},"2027-09-01",{"name":211,"class":41},"The Cleveland Clinic",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":16,"minAge":134,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":4},"100614281","turp-outcome-prediction-calculator-study-100614281","NCT07277556","TURP Outcome Prediction Calculator Study","Identification of Predictive Parameters for Developing a TURP Outcome Calculator for Preoperative Patient Assessment","TURP-SCORE","Inclusion Criteria:\n\n* Male patients aged 18 years or older\n* Clinical diagnosis of benign prostatic hyperplasia (BPH)\n* Indication for TURP based on symptoms or complications\n* Completed preoperative evaluation (IPSS, ultrasound, PSA, uroflowmetry)\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Suspected or confirmed prostate cancer\n* No clinical evidence of BPH\n* Prior urodynamic diagnosis of underactive\u002Fneurogenic bladder\n* Prior prostate surgery\n* Inability to participate in follow-up",{"count":221,"type":21},200,"The goal of this observational study is to identify which preoperative clinical, ultrasound, and uroflowmetry parameters can help predict the success of transurethral resection of the prostate (TURP) in adult male patients with symptomatic benign prostatic hyperplasia (BPH). The main questions it aims to answer are:\n\nWhich preoperative parameters (IPSS, prostate volume, post-void residual urine, Qmax, comorbidities) are associated with successful postoperative outcomes?\n\nCan these parameters be used to develop a non-invasive calculator to estimate the likelihood of TURP success?\n\nParticipants will undergo routine clinical evaluation that is part of standard care, including:\n\n* completion of the IPSS questionnaire\n* digital rectal examination\n* ultrasound measurement of prostate volume and residual urine\n* uroflowmetry (Qmax and voided volume)\n* standard laboratory testing Eligible participants will then undergo TURP as clinically indicated and return for postoperative assessments of symptom improvement and urinary flow parameters.",[27],[225,165,226,65,64,227],"BPH","TURP","Outcome Prediction","2025-12-15",{"date":230,"type":34},"2025-12-19",{"date":232,"type":21},"2026-03-02",{"date":234,"type":21},"2027-12-13",{"name":236,"class":41},"General Hospital Sveti Duh",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":22,"phases":246,"briefSummary":247,"conditions":248,"keywords":249,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":76},"100578933","clinical-study-on-prostate-thermal-vapor-ablation-guided-by-mritrus-fusion-imaging-100578933","NCT06817733","Clinical Study on Prostate Thermal Vapor Ablation Guided by MRI\u002FTRUS Fusion Imaging","Inclusion Criteria:\n\n* Age 45-85 years;\n* International Prostate Symptom Score (IPSS) ≥ 8, indicating moderate to severe Lower Urinary Tract Symptoms (LUTS) that significantly impact quality of life;\n* Poor response to pharmacological treatment or refusal of pharmacological treatment;\n* Prostate volume 30-80 mL;\n* Maximum urinary flow rate (Qmax) \\\u003C 15 mL\u002Fs;\n* Post-void residual urine volume (PVR) \\\u003C 300 mL;\n* Willingness to provide informed consent and participate in postoperative follow-up.\n\nExclusion Criteria:\n\n* Prostate volume \\\u003C 30 mL or \\> 80 mL;\n* Severe urinary tract infection;\n* Preoperative definitive diagnosis of prostate cancer;\n* Known neurogenic bladder, detrusor muscle weakness, urethral stricture, or other non-BPH causes of urinary obstruction;\n* Patients with prostatitis;\n* History of invasive prostate interventions, such as radiofrequency ablation, laser therapy, or microwave treatment;\n* Patients with severe cardiovascular disease, chronic obstructive pulmonary disease, severe diabetes, hepatic or renal dysfunction, or systemic bleeding disorders, as assessed by the investigator to be unsuitable for surgery.","85 Years",{"count":245,"type":21},30,[24],"Objective of the Clinical Trial\n\nThe objective of this clinical trial is to preliminarily assess the feasibility and safety of performing precise prostate thermal vapor ablation under MRI\u002FTURS guidance. The primary questions it aims to address are:\n\nCan precise prostate thermal vapor ablation under MRI\u002FTURS guidance effectively treat benign prostatic hyperplasia (BPH) and alleviate lower urinary tract symptoms (LUTS)? What safety issues may arise in participants after undergoing prostate thermal vapor ablation? Study Procedures Participants Preoperative Evaluation: Participants will undergo comprehensive preoperative assessments, including clinical examinations and laboratory tests.\n\nProcedure: Participants will receive precise prostate thermal vapor ablation under MRI\u002FTURS guidance.\n\nPostoperative Follow-up:\n\nRegular follow-up to reassess prostate volume. Periodic completion of the International Prostate Symptom Score (IPSS) questionnaire.\n\nRegular measurement of maximum urinary flow rate (Qmax) and post-void residual urine volume (PVR).\n\nResearch Team The research team will conduct precise prostate thermal vapor ablation under MRI\u002FTURS guidance for the participants and manage their follow-up assessments.",[27],[250,168,251],"Benign prostatic hyperplasia","MRI-TRUS","2025-12-04",{"date":254,"type":34},"2025-12-05",{"date":256,"type":34},"2025-02-15",{"date":258,"type":21},"2025-12-31",{"name":260,"class":41},"Chinese PLA General Hospital",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":16,"minAge":158,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":270,"conditions":271,"keywords":274,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":4},"100594233","uroflowmetry-curve-types-and-ipss-in-men-with-luts-100594233","NCT07016776","Uroflowmetry Curve Types and IPSS in Men With LUTS","Evaluation of the Association Between Uroflowmetry Curve Patterns and IPSS Domains in Men With Lower Urinary Tract Symptoms","UROFLOW-IPSS","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Male patients aged 40 years or older\n* Presenting with lower urinary tract symptoms (LUTS)\n* Able to complete the IPSS questionnaire\n* Underwent uroflowmetry and serum creatinine testing\n\nExclusion Criteria:\n\n* History of prior prostate surgery\n* Active urinary tract infection\n* Known diagnosis of neurogenic bladder\n* Current use of indwelling urinary catheter",{"count":87,"type":21},"This prospective observational study aims to evaluate the relationship between different uroflowmetry curve types and International Prostate Symptom Score (IPSS) domains in men presenting with lower urinary tract symptoms (LUTS). Participants will undergo routine clinical evaluations including uroflowmetry, laboratory assessments, and completion of the IPSS questionnaire.\n\nEach participant will be classified into one of five predefined uroflowmetry curve types (normal\u002Fbell-shaped, plateau, staccato, intermittent, or tower-like). The IPSS will be analyzed both as a total score and as two subdomains: storage and voiding symptoms. Additional data such as age, comorbidities, medication use, prostate volume, eGFR, and QoL score will also be recorded to assess potential correlations and predictive factors for symptom severity.\n\nThe goal of this study is to better understand how objective urodynamic findings correlate with patient-reported symptoms and to inform clinical decision-making in men with LUTS.",[272,27,273],"Lower Urinary Tract Symptoms (LUTS)","Voiding Dysfunction",[275,65,276,277,278],"International Prostate Symptom Score (IPSS)","Flow curve pattern","Male urinary symptoms","Prospective observational study","2025-08-30",{"date":281,"type":34},"2025-09-03",{"date":283,"type":21},"2025-09-15",{"date":285,"type":21},"2026-06-15",{"name":287,"class":41},"Tarik Emre Sener",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":134,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":76},"100575262","evaluation-of-the-optilume-bph-catheter-system-and-the-rezum-water-vapor-therapy-in-treating-benign-prostatic-hyperplasia-100575262","NCT06769997","Evaluation of the Optilume BPH Catheter System and the Rezum Water Vapor Therapy in Treating Benign Prostatic Hyperplasia","The Optizum Study: A Randomized, Blinded Single Center Study Evaluating the Optilume BPH Catheter System and the Rezum Water Vapor Therapy for the Treatment of Benign Prostatic Hyperplasia","OptiZum","Inclusion Criteria:\n\n* Male subject with symptomatic BPH.\n* Prostate size 30-100g.\n* Able to complete the study protocol.\n\nExclusion Criteria:\n\n* Unable or unwilling to sign the Informed Consent Form (ICF) and\u002For comply with follow-up requirements\n* Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate\n* Any prior minimally invasive intervention (e.g., TUNA, Balloon, Microwave, Rezūm, UroLift) or surgical intervention of the prostate\n* Confirmed or suspected malignancy of prostate or bladder\n* Active urinary tract infection (UTI) confirmed by culture\n* History of overt urinary incontinence requiring use of pads NOTE: Pad usage for post-micturition dribble is acceptable\n* Presence of confounding diagnoses impacting lower urinary tract symptoms or bladder function (e.g., urethral strictures, bladder neck contracture, neurogenic bladder, detrusor instability, bladder stones, etc.)\n* History of chronic urinary retention (e.g., PVR ≥300mL on two separate occasions, or catheter dependent drainage)\n* Anatomy (e.g., presence of false passage or size of meatus) is not suitable for treatment with the Optilume BPH Catheter System\n* Significant obstruction from median lobe (investigator opinion)\n* Disease or other health condition that is not suitable for this study",{"count":297,"type":21},100,[24],"Lower urinary symptoms (LUTS) affect older men and their frequency and severity increase with age. According to Berry et al., the histological diagnosis of benign prostatic hyperplasia (BPH) increases from 25% in the group age between 40 to 49 years to 80% in the group age between 70 to 79 years (1). However, this hyperplasia can lead to a bladder outlet obstruction (BOO) secondary to benign prostatic enlargement (BPE), causing storage and voiding symptoms, associated with a considerable impairment of the quality of life (2).\n\nSurgical therapy of BPH has continuously evolved in recent years. The current gold standard for the endoscopic treatment of BPH is the transurethral resection of the prostate (TURP). Other innovative techniques were developed including Urolift, transurethral laser enucleation (holmium, thulium) and Aquablation therapy. One of the latest technologies for the management of BPH are Optilume BPH Catheter System (Optilume®, Urotronic Inc, Minneapolis, USA) and Rezum Water Vapor Therapy (Rezum System, Bostocn Scientific, Marlborough, MA).\n\nThe purpose of the present study is to compare between patient experience, symptom relief and functional improvement when using the Optilume BPH Catheter System (Optilume®, Urotronic Inc, Minneapolis, USA) and Rezum Water Vapor Therapy (Rezum System, Boston Scientific, Marlborough, MA).",[27,301],"Lower Urinary Track Symptoms",[174,301,225,165,303,168],"Optilume","2025-07-14",{"date":306,"type":34},"2025-07-17",{"date":308,"type":34},"2025-05-09",{"date":310,"type":21},"2027-01",{"name":312,"class":41},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":320,"minAge":321,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":76},"100575459","desflurane-potentially-induces-postoperative-cognitive-dysfunction-in-elderly-patients-undergoing-perioperative-procedures-by-modulating-cdc42-and-clock-proteins-100575459","NCT06772558","Desflurane Potentially Induces Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Perioperative Procedures by Modulating Cdc42 and Clock Proteins","The Potential Mechanism by Which Desflurane Induces Postoperative Cognitive Dysfunction in Elderly Perioperative Patients Involves the Modulation of Cdc42 and Clock Proteins, and Their Related Signaling Pathways.","Inclusion Criteria:\n\n* Age \\> 70 years\n* American Society of Anesthesiologists (ASA) physical status classification I-III\n* Scheduled to undergo elective surgery requiring general anesthesia with desflurane\n* Able and willing to provide voluntary written informed consent\n* Able to understand the study procedures and complete follow-up assessments\n\nExclusion Criteria:\n\n* Pre-existing diagnosis of dementia or any other neurodegenerative disease that could affect cognitive function\n* Preoperative Montreal Cognitive Assessment (MoCA) score \\\u003C 20\n* History of severe psychiatric disorders, including psychosis, severe depression, or bipolar disorder\n* Unstable angina, uncontrolled hypertension, or a history of myocardial infarction within the past 6 months\n* Severe chronic obstructive pulmonary disease (COPD) with significant respiratory compromise, or other significant respiratory disease\n* Severe hepatic or renal impairment, defined as Child-Pugh class C for liver disease, or glomerular filtration rate (GFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m2 for kidney disease\n* History of stroke, transient ischemic attack (TIA), or other significant neurological disorders\n* History of alcohol or drug abuse\n* Patients with visual, auditory, or language impairments that would interfere with cognitive testing.\n* Known allergy or contraindication to any of the study drugs\n* Other conditions at the discretion of the investigator that could interfere with the conduct of the study or the interpretation of the results","ALL","70 Years",{"count":323,"type":21},60,[24],"This clinical trial investigates whether desflurane induces postoperative cognitive dysfunction (POCD) in elderly patients undergoing perioperative procedures by modulating Cdc42 and Clock proteins. The primary research questions are: (1) Does desflurane administration contribute to POCD in this patient population? and (2) Are alterations in Cdc42 and Clock protein levels associated with desflurane-induced POCD in elderly patients? To address these questions, elderly patients will be administered desflurane for anesthesia maintenance. Postoperative assessments will then compare blood levels of Cdc42 and Clock proteins, and examine related signaling pathways, between a control group and a POCD group.\n\nStudy participants will receive desflurane anesthesia maintained at a Bispectral Index (BIS) value of 40-60. Postoperative cognitive function will be assessed on the second day using the Montreal Cognitive Assessment (MoCA), and participants will be categorized into either a control group or a POCD group based on MoCA performance. Cognitive function and blood levels of Cdc42 and Clock proteins will be recorded. Furthermore, the study will also investigate associated signaling pathways.",[327,328,27,329,330],"Avascular Necrosis of the Femoral Head","Coronary Artery Disease (CAD)","Cholecystitis","Knee Osteoarthritis","2025-01-12",{"date":333,"type":34},"2025-01-14",{"date":335,"type":21},"2025-02-01",{"date":337,"type":21},"2025-05-10",{"name":339,"class":41},"Xiaguang Duan",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":344,"acronym":4,"eligibilityCriteria":345,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":18,"enrollmentInfo":346,"targetDuration":4,"studyType":22,"phases":348,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":76},"100520923","phase-2-effects-of-tnf-blockade-on-human-bphluts-100520923","NCT06062875","Effects of TNF Blockade on Human BPH\u002FLUTS","Inclusion Criteria:\n\n* Male sex\n* Age 45-80 years\n* Diagnosed by physician with BPH\n* Prostate volume ≥ 60mL\n* IPSS ≥ 8\n* Able and willing to complete questionnaires\n* Able and willing to provide informed consent\n* Able to read, write, and speak in English\n* No prior treatment with TNF inhibitor (adalimumab, etanercept, infliximab, certolizumab, golimumab)\n* No plans to move from study area in the next 6 months\n\nDeferral Criteria:\n\n* Microscopic hematuria without appropriate workup per AUA\u002FSociety of Urodynamics, Female Pelvic Medicine \\& Urogenital Reconstruction (SUFU) Guidelines\n* Positive urine culture\n\nExclusion Criteria:\n\n* Female sex or intersex\n* Age \\\u003C 45 or \\> 80 years\n* Being a prisoner or detainee\n* Urinary retention with need for catheterization\n* Gross hematuria\n* Contraindication to treatment with adalimumab (e.g., presence of sepsis or active infection, active tuberculosis, Hepatitis B infection, invasive fungal infection, lymphoma, leukemia or other active malignancy, congestive heart failure, significant hematologic abnormality, allergy to adalimumab or its components, anti-drug antibodies, congestive heart failure)\n* Diagnosis of autoimmune disease (rheumatoid arthritis, plaque psoriasis, ulcerative colitis, Crohn's disease, hidradenitis suppurativa, spondyloarthritis)\n* Interstitial cystitis\n* Pelvic or endoscopic genitourinary surgery within the preceding 6 months (not including diagnostic cystoscopy)\n* History of lower urinary tract or pelvic malignancy including prostate cancer; history of pelvic radiation therapy\n* Ongoing symptomatic urethral stricture\n* Current chemotherapy or other cancer therapy\n* Severe neurological or psychiatric disorder that would prevent study participation (e.g., bipolar disorder, psychotic disorder, Alzheimer's Disease)\n* Current moderate or severe substance use disorder",{"count":347,"type":21},70,[349],"PHASE2","Specific Aim 1. To evaluate the efficacy of TNF antagonist action in BPH\u002FLUTS Specific Aim 2. Define the consequences of TNF antagonist therapy on prostate tissue Specific Aim 3. Identify genetic predictors to stratify patients with differential response to TNF-antagonist therapy.",[27],"2024-11-18",{"date":354,"type":34},"2024-11-21",{"date":356,"type":34},"2024-01-24",{"date":358,"type":21},"2028-06-01",{"name":360,"class":41},"Endeavor Health",{"id":362,"slug":363,"hasResults":11,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":22,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":76},"100405555","aquablation-vs-holmium-laser-enucleation-of-the-prostate-in-the-treatment-of-benign-prostatic-hyperplasia-in-medium-to-large-size-prostates-100405555","NCT04560907","Aquablation vs. Holmium Laser Enucleation of the Prostate in the Treatment of Benign Prostatic Hyperplasia in Medium to Large Size Prostates","Aquablation vs. Holmium Laser Enucleation of the Prostate in the Treatment of Benign Prostatic Hyperplasia in Medium to Large Size Prostates: A Prospective Randomized Trial","ATHLETE","Inclusion Criteria:\n\n* Men ≥45 years of age\n\n  * Patient must be a candidate for HoLEP\n  * Refractory to medical therapy or patient is not willing to consider (further) medical treatment\n  * Patient has a prostate size of at least 50 ml and not more than 150ml, measured by transrectal ultrasound (TRUS)\n  * IPSS ≥12\n  * QoL≥3\n  * Qmax ≤ 15 ml\u002Fs with a minimum voided volume ≥ 125 ml or patient in urinary retention\n  * Written informed consent\n\nExclusion Criteria:\n\n* Neurogenic lower urinary tract dysfunction\n\n  * Urethral stenosis\n  * Preinterventionally proven adenocarcinoma of the prostate\n  * Nickel allergy\n  * Not able to complete questionnaires due to cognitive or thought disorders\n  * Language skills insufficient for informed consent and \u002F or completion of questionnaires",{"count":370,"type":21},120,[24],"Benign prostatic hyperplasia (BPH) is one of the most common diseases in men. As BPH progresses, surgical treatments often become necessary. Holmium enucleation of the prostate (HoLEP) is an established procedure in the surgical treatment of BPH, especially for medium to large prostates. The long learning curve, the length of surgery, and expensive equipment still limit the availability of HoLEP to a few specialized centers.\n\nRecently, a new method for treating BPH called aquablation has become commercially available. This technique uses real-time ultrasound imaging in combination with a robotic high-pressure water jet programmed and guided by the surgeon to resect prostate tissue. A RCT has shown functional results similar to transurethral resection of the prostate (TURP) for small to medium size prostates .\n\nHowever, so far there are no controlled studies assessing whether Aquablation provides patient reported and functional outcomes that are non-inferior compared to HoLEP in medium size to large prostates (the latter cannot be operated by TURP due to its size limitations).\n\nAs aquablation offers some obvious advantages compared to HoLEP regarding learning curve and operation time, the aim of this study is to test whether efficacy and safety of aquablation are non- inferior compared to HoLEP in patients with medium to large size prostates, which would clearly support the use of aquablation and change everyday clinical practice.",[27],"2021-01-07",{"date":376,"type":34},"2021-01-08",{"date":378,"type":21},"2021-01-05",{"date":380,"type":21},"2027-11",{"name":382,"class":41},"Dr. med. Gautier Müllhaupt"]